Blood-based delta-HLD methylation test for detecting colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

CASCADE is a proof-of-concept case-control study comparing blood (plasma cfDNA) and tumor tissue from individuals with histologically confirmed colorectal cancer to controls with negative colonoscopy. Epiliquid's bioinformatic pipeline identifies and ranks colorectal-specific methylation biomarkers, which are detected using delta-HLD, a sequential enzymatic pre-treatment combined with PCR that enables sensitive, multiplexed detection. The study will measure diagnostic performance metrics including sensitivity, specificity, and concordance between blood and tissue in an average-risk population. Results will support validation of the integrated platform as a minimally invasive diagnostic approach for colorectal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Candidate for colonoscopy or colorectal surgery
* Willing and able to provide informed consent
* Able to provide blood and/or tissue sample before treatment or resection

Exclusion Criteria:

* Prior history of colorectal cancer
* Inflammatory bowel disease
* Known hereditary cancer syndromes (e.g., Lynch, FAP)
* Other active malignancies
* Recent chemotherapy or immunosuppressive treatment

Where it's running

• Epiliquid
  Mendoza, Argentina Recruiting

Study contacts

• Study coordinator: Dr. Victoria Bocanegra, MD, PhD.
• Email: victoria.bocanegra@epiliquid.com
• Phone: +5492616603254

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Personal cancer risk testing using genetic, blood, and tumor monitoring

  This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07469709

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Colorectal Cancer Screening Outreach for Better Adherence

  This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.

  Recruiting Yale University · New Haven, Connecticut · NCT07345676

• MBRC-201 dose-finding and safety in advanced metastatic solid tumors

  We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.

  Recruiting at 7 sites Phase 1/2 MBrace Therapeutics · San Francisco, California and 6 other locations · NCT07145255

• Low-dose trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer

  This will try a lower-dose trifluridine/tipiracil plus bevacizumab regimen for people with metastatic colorectal cancer who have progressed after at least two prior treatments.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Sanming and 1 other locations · NCT07085169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.